24/7 Market News Snapshot 26 August, 2025 – Marker Therapeutics, Inc. Common Stock (NASDAQ:MRKR)

August 26, 2025

DENVER, Colo., 26 August, 2025 (www.247marketnews.com) – (NASDAQ:MRKR) are discussed in this article.
Marker Therapeutics, Inc. (MRKR) is experiencing significant market momentum, with its stock price soaring by 28.81% to reach $1.623 during pre-market trading, up from the previous close of $1.260. This impressive performance has captured investor attention, as evidenced by a trading volume of 8.10 million shares. Such volatility hints at increasing confidence in the company’s innovative developments within the biotechnology sector.

The surge in market activity coincides with the announcement of promising results from the ongoing Phase 1 APOLLO study concerning MT-601, a revolutionary Multi-Antigen Recognizing (MAR) T cell therapy specifically designed for patients with relapsed B cell lymphoma. Initial findings from this multicenter, open-label trial indicate a remarkable 66% objective response rate among participants with Non-Hodgkin Lymphoma (NHL), with half of those achieving complete remission.

MT-601 is being evaluated for patients who have either relapsed after anti-CD19 CAR-T cell therapy or are deemed ineligible for such treatments. To date, the study has treated 24 patients, demonstrating a favorable safety profile, as no dose-limiting toxicities or symptoms of immune-effector cell-associated neurotoxicity syndrome have been reported. The next phase will explore MT-601 at its maximum dosage of 400×10^6 cells, focusing on patients with Diffuse Large B Cell Lymphoma (DLBCL).

Dr. Juan Vera, President and CEO of Marker Therapeutics, expressed enthusiasm regarding the study’s progress, emphasizing the therapy’s potential impact on meeting the critical needs of heavily pre-treated patients. As additional data becomes available, a live online webcast is scheduled for today at 8:30 a.m. EDT, where further insights and findings will be presented, promising to shed light on the future impact of MT-601 in oncology.

Related news for (MRKR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.